ArticleMolecular biology reports2026
Therapeutic potential of a novel spirocyclic molecule in a murine model of peripheral nerve injury mediated via anti-inflammatory and neuroprotective properties.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral nervous system injury (PNI) is a leading cause of long-term disability worldwide, with traumatic damage to major nerves such as the sciatic nerve, facial nerve, and brachial plexus severely impairing motor function, reducing life expectancy, and predisposing to mood disorders, thereby imposing a substantial socioeconomic burden. Effective therapies to limit PNI-induced neural damage, particularly in sciatic nerve injury (SNI), remain inadequate, largely due to an incomplete understanding of the underlying molecular mechanisms.
objectiveTo evaluate the efficacy of the CNS-active Spiro tricyclic compound IM-1725-RS-109a in improving motor deficits and modulating injury-related molecular markers in a mouse model of SNI.
methodsSciatic nerve injury was induced in C57BL/6NCrl mice using a standardized crush-force technique. The spiro compound IM-1725-RS-109a, previously shown to be effective in an ischemic stroke mouse model, was administered intraperitoneally at a daily dose of 5 mg/kg for 5 days following injury.
resultsTreatment with IM-1725-RS-109a significantly restored motor behavioral performance in OFT, rotarod, and pole tests in SNI mice compared with SNI group controls. Marked differences were observed between groups receiving treatment initiated at different post-injury time points. qRT-PCR and Western Blot analysis revealed significant increases in neurogenesis and reductions in inflammation in the treatment groups.
conclusionIM-1725-RS-109a confers functional and molecular neuroprotection in a mouse model of sciatic nerve injury, supporting the peripheral neuroprotective and anti-inflammatory potential of CNS-active spiro tricyclic compounds. These findings suggest that the compound may be a promising candidate for further development as a therapeutic strategy for PNI.
Indexed as
Identifiers
42047912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.